^
Association details:
| Biomarker: | XIRP2 mutation + TMB-H |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
XIRP2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.
Published date:
05/26/2022
Excerpt:
NSCLC patients with XIRP2 mutation were significantly associated with better PFS (HR = 0.4; 95% CI, 0.21-0.75; P = 0.003) after ICIs therapy, compared with those with wide-type XIRP2. XIRP2 mutation were associated with increased TMB (P< 0.001).
DOI:
10.1200/JCO.2022.40.16_suppl.e14573
